This study was to investigate the pharmacokinetics of tolterodine, substrate of CYP2D6 in healthy subject in relation to the presence of HNF-4A G60D variant.

NCT01181505

Conditions

1. Genotype Guided(HNF4a)
2. Healthy Subjects

Interventions

1. Drug: Tolterodine

STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study. --- G60D ---

STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study This study was to investigate the pharmacokinetics of tolterodine, substrate of CYP2D6 in healthy subject in relation to the presence of HNF-4A G60D variant. --- G60D ---

STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study This study was to investigate the pharmacokinetics of tolterodine, substrate of CYP2D6 in healthy subject in relation to the presence of HNF-4A G60D variant. --- G60D --- --- G60D ---

Inclusion Criteria: - Healthy subject whose HNF4a and CYP2D6 genotype ware determined Exclusion Criteria: - Subject whose HNF4a and CYP2D6 genotype ware not determined Inclusion Criteria: - Healthy subject whose HNF4a and CYP2D6 genotype ware determined Exclusion Criteria: - Subject whose HNF4a and CYP2D6 genotype ware not determined Genotype Guided(HNF4a) Healthy Subjects After a single oral administration of 2 mg tolterodine in 31 healthy subjects (6 with the heterozygous mutation of HNF-4A G60D vs 25 subjects with wild type of that whose CYP2D6 genotype and gender were matched with variant group), blood were collected for 24hrs. --- G60D ---